Paclitaxel has become part of the standard chemotherapeutic armamentarium for a wide range of solid tumours. Treatment with paclitaxel, however, is associated with specific toxicities, among which is peripheral sensory and motor neuropathy. Paclitaxel-induced neurotoxicity, albeit rarely life-threatening, often necessitates dose reduction or discontinuation, which may compromise disease control. Although long-term follow-up data are scarce, it has been reported that many breast cancer patients experience persistent numbness of extremities at 12 months after the completion of adjuvant paclitaxel-containing therapy with a frequency of 3--12% (grade 0), 46 --75% (grade 1), 12--21% (grade 2) and 4--8% (grade 3) ([@bib11]; [@bib28]). In addition, a negative impact on the quality of life was documented in affected patients. An imposing challenge in the management of peripheral neuropathy arises from the considerable variation in the time-point of occurrence and the severity of symptoms among treated patients.

Multiple factors influencing peripheral neuropathy development and severity have been reported. The effect of paclitaxel dosing and schedule is well recognised. Generally, paclitaxel-induced peripheral neuropathy occurs more frequently and at greater severity with prolonged treatment duration, higher cumulative dose and higher dose per cycle ([@bib14]; [@bib23]). The concomitant use of neurotoxic agents, that is, cisplatin, contributes to the likelihood of development. The addition of either capecitabine or bevacizumab to a taxane, that is, paclitaxel or docetaxel, did not lead to increased rates of taxane-specific toxicities, albeit other toxicities associated with capecitabine (hand-foot syndrome, gastrointestinal toxicities) ([@bib24]) or bevacizumab (hypertension, proteinuria and thromboembolic events) ([@bib7]) occurred more frequently. Besides treatment-related factors, patient characteristics predisposing to paclitaxel-induced peripheral neuropathy have been identified and include women, older age, body surface area (BSA) and hyperglycaemia ([@bib14]; [@bib23]; [@bib26]), although their clinical relevance needs further investigation.

Heterogeneity among individuals with respect to susceptibility to paclitaxel-induced peripheral neuropathy may also be attributed to individual genetic differences, among which single-nucleotide polymorphism (SNPs) are the most common form. SNPs in genes involved in paclitaxel metabolic pathways, such as *ABCB1*, *CYP2C8* and *CYP3A4*, have been shown to modulate paclitaxel pharmacokinetics and may, therefore, be useful for toxicity prediction ([@bib9]). *CYP2C8*\*3 comprising c.-416G\>A (rs11572080) and c.1196A\>G (rs10509681) in perfect linkage disequilibrium has been related to decreased metabolism of paclitaxel and associated with a higher risk of peripheral neuropathy ([@bib10]; [@bib19]; [@bib4]; [@bib13]). This observation, however, was not consistently reported ([@bib22]; [@bib6], [@bib5]; [@bib8]). Of interest, a newly reported genetic variant of *CYP3A4,* c.522-191C\>T (*CYP3A4\*22*, rs35599367), has been associated with lower enzymatic activity as illustrated by reduced dose requirements of CYP3A4-metabolised drugs, such as statins ([@bib30]). In the context of paclitaxel, De Graan *et al* ([@bib8]) have described that the presence of a *CYP3A4* c.522-191 T-allele conferred a higher risk of severe peripheral neuropathy, but the carrier status was not associated with altered pharmacokinetics.

In recent studies, several SNPs possibly involved in paclitaxel-induced neurotoxicity have been identified in genes that play a role in neuronal processes. Leandro-García *et al* ([@bib17]) have found that the highly linked c.-101T\>C (rs909964) and c.-112A\>G (rs909965) variants in *TUBB2A*, a microtubule-associated protein, were associated with a lower risk of peripheral neuropathy. Genome-wide association studies (GWAS) have pointed towards SNPs located in genes encoding exchange factors involved in the myelination of peripheral nerves (*FGD4*) ([@bib3]) or proteins related to neuronal development and regeneration (*EPHA5*) ([@bib3]; [@bib16]). Baldwin *et al* ([@bib3]) have identified that *FGD4* c.2044-236G\>A (rs10771973) was associated with sensory peripheral neuropathy among paclitaxel-treated patients. In two independent GWAS cohorts treated with paclitaxel, *EPHA5* c.2895G\>A (rs7349683) was found as a predictive marker for peripheral neuropathy ([@bib3]; [@bib16]). The functional role of these SNPs in the context of paclitaxel-induced neurotoxicity needs to be characterised.

Further confirmation is necessary to establish the predictive ability of particular SNPs for neurotoxicity among patients receiving paclitaxel. In the present study we analysed a series of candidate SNPs for an association with this adverse event (AE) in a large, well-characterised cohort of HER2-negative metastatic breast cancer (MBC) patients that received first-line paclitaxel-containing chemotherapy.

Materials and methods
=====================

Patient cohort
--------------

The study population included 188 women with HER2-negative MBC, who were previously enroled in the multicenter, randomised, phase II ATX trial (BOOG2006-06; EudraCT number 2006-006058-83) ([@bib15]). Pharmacogenetic analysis, a preplanned part of the original trial design, was approved by the institutional review board of all participating hospitals and was conducted in accordance with the Declaration of Helsinki. Separate informed consent from patients was required before participation in this study. Blood was collected and serum was stored at −80 °C until DNA isolation.

Treatment
---------

Eligible patients received first-line treatment randomly allocated to the AT arm consisting of paclitaxel (90 mg m^−2^ on days 1, 8 and 15) and bevacizumab (10 mg kg^−1^ on days 1 and 8) repeated in a 4-week schedule for 24 weeks, followed by bevacizumab (15 mgkg^−1^ on day 1) every 3 weeks thereafter, or to the ATX arm consisting of paclitaxel (90 mg m^−2^ on days 1 and 8), bevacizumab (15 mg kg^−1^ on day 1) and capecitabine (825 mg m^−2^ orally twice daily on days 1--14) repeated in a 3-week schedule for 24 weeks, followed by bevacizumab and capecitabine at the same dose every 3 weeks thereafter. Treatment was continued until disease progression, unmanageable toxicity or withdrawal of consent, whichever came first.

Evaluation of peripheral neuropathy and paclitaxel dose modification
--------------------------------------------------------------------

Peripheral neuropathy was graded each cycle according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE version 3.0). Dose modification of paclitaxel was based on relevant treatment-related AEs and was documented in case report forms. Paclitaxel dose was reduced to 60 mg m^−2^ for a second occurrence of grade 2 treatment-related AE or any occurrence of grade 3 treatment-related AEs. Paclitaxel was terminated at third occurrence of grade 2, second occurrence of grade 3 or at first occurrence of a grade 4 AE deemed paclitaxel-related.

Genetic polymorphisms and genotyping
------------------------------------

Five polymorphisms in five genes were examined ([Table 1](#tbl1){ref-type="table"}). Germline DNA was isolated from 1 ml of serum on a MagNaPure Compact Instrument with a MagNaPure Compact Total Nucleic Acid Isolation kit (Roche Diagnostics, Almere, The Netherlands). Owing to a limited amount of extracted serum DNA, a pre-amplification step was performed with a PreAmp Master Mix Kit according to the manufacturer\'s instruction (Life Technologies, Bleiswijk, The Netherlands). Genotyping of SNPs *CYP2C8*\*3 (c.416G\>A, C\_\_25625794_10, rs11572080), *CYP3A4*\*22 (c.522-191C\>T, C_59013445_10, rs35599367), *FGD4* (c.2044-236G\>A, AH890NA \[custom assay\], rs10771973) and *EPHA5* (c.2895G\>A, C\_\_\_1336545_30, rs7349683) was performed by real-time PCR run on the LightCycler 480II system (Roche Diagnostics) using commercially available predesigned TaqMan probes (Life Technologies). *TUBB2A* (c.-101T\>C, rs909964) genotyping was performed using a Kompetitive Allele Specific PCR (KASP) genotyping assay (LGC Genomics, Teddington, UK). All genotyping was performed in a blinded fashion including water as a negative control. As a quality control, 5% of all DNA samples were measured in duplicate for each genotyping assay. Raw data were analysed with LightCycler 480 software package (release 1.5.0 SP4, Roche Diagnostics).

Statistical analysis
--------------------

Data are presented as median with range, actual number and percentage unless otherwise specified. Mann--Whitney *U* test was used to analyse continuous variables between two groups and the Pearson\'s χ^2^ was used for categorical variables. Deviation from the Hardy--Weinberg equilibrium was tested using the Pearson\'s χ^2^ test. The relative dose intensity was calculated as the ratio between paclitaxel dose delivered in a time period (mg m^−2 ^week^−1^) and the planned dose considering no dose modification.

SNPs were assessed univariately by the Kaplan--Meier method and Gehan--Breslow--Wilcoxon test for two toxicity endpoints: (1) cumulative paclitaxel dose (mg m^−2^) until grade ⩾1 peripheral neuropathy and (2) cumulative paclitaxel dose (mg m^−2^) until first dose reduction (or study therapy withdrawal) from toxicity deemed unacceptable by treating doctors. Patients not experiencing peripheral neuropathy or dose reduction were censored for the total cumulative dose. SNPs with a *P*⩽0.10 were selected for multivariate Cox proportional hazards model to estimate hazard ratio (HR) and 95% CI.

The following demographic and clinicopathological factors were examined for the association with the two toxicity endpoints using the Kaplan--Meier method and univariate Cox proportional hazards model: Eastern Cooperative Oncology Group performance status (0 *vs* 1), age (\<65 *vs* ⩾65 years), BSA (continuous), oestrogen and/or progesterone receptor status (positive *vs* negative), bone-only disease (yes *vs* no), previous (neo)adjuvant chemotherapy (yes *vs* no), previous primary radiotherapy (yes *vs* no), previous palliative radiotherapy (yes *vs* no) and the number of metastases (1 *vs* 2 *vs* ⩾3). Clinical variables with a *P*⩽0.10 were considered as covariates in the multivariate analysis. The risk of paclitaxel-related peripheral neuropathy is known to depend on the cumulative dose. Without dose modification, AT-treated patients received a higher cumulative paclitaxel dose than ATX-treated patients (maximum of 1620 *vs* 1440 mg m^−2^, respectively). In practice, the total cumulative dose varied widely and there was considerable overlap of patients who received similar cumulative doses regardless treatment arm. To account for between-arm and within-arm differences, patients were categorised into tertile groups of increasing total cumulative dose of paclitaxel and this covariate was included in the multivariate Cox regression analysis.

SNPs were analysed according to the best fitting genetic model in univariate (additive, dominant or recessive) and multivariate analyses (multiplicative). No correction for multiple comparisons was done due to the exploratory nature of this study. All statistical analyses were performed using SPSS version 20 (Chicago, IL, USA). Statistical significance was defined as *P*⩽0.05.

Results
=======

Study population and paclitaxel treatment
-----------------------------------------

Clinical characteristics of the 188 patients are shown in [Table 2](#tbl2){ref-type="table"}. A total of 95 patients were assigned to the AT arm of weekly paclitaxel for 3 weeks on/one week off and 93 patients to the ATX arm of weekly paclitaxel for 2 weeks on/one week off. Demographic and disease characteristics at baseline were well balanced between the treatment arms ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). All patients received at least one dose of paclitaxel with a median cumulative dose of 1409 mg m^−2^ ([Table 3](#tbl3){ref-type="table"}). Median relative dose intensity of paclitaxel was 0.94. Owing to the different schedules, as anticipated, the cumulative dose of paclitaxel was higher in AT as compared with ATX (*P*\<0.001). The intended dose of paclitaxel delivered, however, did not differ between the two treatment arms according to the similarity in median relative dose intensities (*P*=0.28).

Paclitaxel-induced peripheral neuropathy and dose reduction
-----------------------------------------------------------

The rates of highest grade peripheral neuropathy experienced per patient are shown in [Table 3](#tbl3){ref-type="table"}. There were no cases of grade 4 peripheral neuropathy. A total of 126 patients (67%) experienced grade ⩾1 peripheral neuropathy following the initiation of paclitaxel-based therapy: 64.2% in the AT *vs* 69.9% in the ATX arm, *P=*0.41. The rate of dose reduction in the study population was 46% and was similar in both treatment arms (*P=*0.57). AEs that led to dose reduction of paclitaxel are shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. There was no significant difference in the rate of grade ⩾1 peripheral neuropathy between patients requiring paclitaxel dose reduction and those without dose reduction (45% *vs* 47%, *P=*0.83).

Results of the univariate Cox analysis for clinical variables in relation with two toxicity endpoints are summarised in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}. Of the demographic and clinicopathological factors, age ⩾65 years was associated with an increased risk of cumulative paclitaxel dose-dependent grade ⩾1 peripheral neuropathy (HR=1.87, 95% CI 1.17--2.97, *P=*0.008) and was included in the Cox proportional hazards models. BSA has previously been identified as a risk factor for the development of taxane-induced neuropathy ([@bib26]) and was, therefore, included as a covariate in the analysis of peripheral neuropathy. None of the clinical variables were associated with dose reduction.

Allele frequencies and analyses
-------------------------------

The allele frequency of SNPs is shown in [Table 1](#tbl1){ref-type="table"}. Although patients\' ethnicity was not collected, the vast majority of patients were of Caucasian origin. The allele frequency of SNPs was similar to that reported in the Caucasian population according to the NCBI SNP database (dbSNP) ([@bib27]). The overall success rate of SNP genotyping was \>90% ([Table 1](#tbl1){ref-type="table"}). *CYP3A4* c.522-191C\>T was analysed under a dominant genetic model (CC *vs* TT+TC), as only one patient was homozygous for the T-allele. The distribution of SNPs in the two treatment arms is presented in [Supplementary Table 4](#sup1){ref-type="supplementary-material"}.

Genetic polymorphisms and peripheral neuropathy or paclitaxel dose reduction
----------------------------------------------------------------------------

Significant associations in the univariate and multivariate analyses are presented in [Table 4](#tbl4){ref-type="table"}. *CYP2C8*\*3 was univariately associated with cumulative dose-dependent peripheral neuropathy. Carriers of a *CYP2C8*\*3 variant received a significantly lower cumulative paclitaxel dose until first onset of grade ⩾1 peripheral neuropathy than non-carriers (Gehan--Breslow--Wilcoxon *P*=0.018, [Figure 1](#fig1){ref-type="fig"}). In the multivariate analysis adjusted for age, BSA and total cumulative paclitaxel dose, *CYP2C8*\*3 variant was independently associated with an increased risk of grade ⩾1 peripheral neuropathy (HR=1.59, 95% CI 1.01--2.52, *P*=0.045). No significant associations were detected between other SNPs and this peripheral neuropathy endpoint.

Analysis of the cumulative dose until first paclitaxel dose reduction showed an association for *FGD4* c.2044-236G\>A. Under a dominant model, the presence of an A-allele was significantly associated with a lower cumulative paclitaxel dose until first reduction compared with the GG genotype (Gehan--Breslow--Wilcoxon *P*=0.044, [Figure 2A](#fig2){ref-type="fig"}). This was associated with an increased risk of paclitaxel dose reduction in the multivariate analysis adjusted for total cumulative paclitaxel dose (HR per A-allele=1.38, 95% CI 1.02--1.86, *P*=0.036). Interestingly, under a dominant model, the presence of a C-allele in *TUBB2A* c.-101T\>C had a possible association with dose reduction (Gehan--Breslow--Wilcoxon *P*=0.10, [Figure 2B](#fig2){ref-type="fig"}) and was, therefore, selected for calculating the HR. This association with paclitaxel dose reduction was not significant in the multivariate analysis (HR per C-allele=0.76, 95% CI 0.53--1.10, *P*=0.14).

Discussion
==========

Pharmacogenetic studies have revealed many candidate SNPs for the prediction of paclitaxel-induced AEs, but reported findings were conflicting. An explanation for this heterogeneity may reside in differences in study design, sample size, definition of toxicity, treatment duration, dose and concomitant neurotoxic medication ([@bib9]). In the current study, we focused on a relatively homogeneous group of women with MBC, who were enroled in the phase II ATX trial according to predefined in- and exclusion criteria. All women received a defined dose and a fixed duration of paclitaxel-based therapy. Detailed information with regard to toxicities, dose reduction and received paclitaxel dose were recorded. Therefore, our results may likely provide credible information regarding the predictive value of genetic polymorphisms.

Maximum severity of peripheral neuropathy defined by NCI-CTCAE was used as main study endpoint in most pharmacogenetic studies. Peripheral neuropathy is, however, known to be a cumulative dose-dependent toxicity and occurs earlier in patients receiving higher doses given once every 3 weeks than in lower doses given more frequently ([@bib14]). We choose grade ⩾1 as a cutoff of this AE, because of its gradual development in the weekly low dose paclitaxel schedule. The cumulative dose until development of toxicity has been employed in the current study and more recent analyses ([@bib19]; [@bib3]; [@bib17], [@bib16]; [@bib13]; [@bib1]). This approach takes into account the variable treatment duration among advanced cancer patients by censoring those who terminated treatment early due to disease progression or death.

We considered the cumulative dose until first dose reduction of paclitaxel due to a treatment-related AE another clinically meaningful endpoint that generally represents deterioration of the patient\'s general condition. As paclitaxel treatment is associated with a broad spectrum of clinically relevant toxicities ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}), it could be speculated that this endpoint captures the overall toxic effects of paclitaxel. Moreover, dose reduction is common practice in oncology allowing symptom alleviation and restoring quality of life. Clinical studies have suggested that dose reduction in chemotherapy may compromise tumour control and survival prospects in treated patients ([@bib21]; [@bib20]), although evidence concerning this topic is scarce. Future evaluation of this study endpoint, in particular for the relationship with clinical outcome, should help to clarity its relevance for pharmacogenetic studies.

The current analysis demonstrated that carriers of a *CYP2C8*\*3 variant (c.416G\>A) received a significantly lower cumulative dose of paclitaxel until the development of grade ⩾1 peripheral neuropathy (*P*=0.018). Multivariate analysis adjusted for age, BSA and differences in the total cumulative paclitaxel dose confirmed an increased risk for *CYP2C8\*3* variant carriers compared with the non-carriers indicating *CYP2C8*\*3 as a potential marker of paclitaxel-related peripheral neuropathy. CYP2C8 represents a major metabolising enzyme that catalyses the formation of 6α-hydroxypaclitaxel, rendering paclitaxel inactive ([@bib29]). Of interest, *CYP2C8*\*3 (c.416G\>A) has been documented to contribute to the attenuation of CYP2C8 activity leading to a decreased clearance of paclitaxel ([@bib2]; [@bib10]). Therefore, although pharmacokinetics was not analysed in the present study, one may speculate that *CYP2C8*\*3 variant carriers are at an increased risk of neurotoxicity as a consequence of increased paclitaxel exposure.

*CYP2C8*\*3 (c.416G\>A and/or c.1196A\>G) has been examined in previous pharmacogenetic studies on paclitaxel-induced neurotoxicity. Hertz *et al* ([@bib13]) have analysed *CYP2C8*\*3 (c.1196A\>G) in a European-American population of 209 women with breast cancer, who received different schedules of (neo)adjuvant paclitaxel-containing therapy. The presence of a *CYP2C8*\*3 allele (c.1196 G) was associated with an increased risk of grade ⩾2 neurotoxicity: each allele had an HR of 1.95 (*P*=0.031) in a final model that included diabetes history. Subsequently, this association was validated in an African-American cohort (*n*=107) resulting in an HR of 3.30 (*P*=0.043) per allele. In a total number of 411 patients consisting of mixed races, the association between *CYP2C8*\*3 (c.1196A\>G) and risk of grade ⩾2 neuropathy was still significant (HR 1.98, *P*=0.004). In their preceding study on 109 patients that were part of the mixed-race cohort, the same group had reported that carriers of a *CYP2C8*\*3 variant (defined as a c.1196 G-allele and/or c.416 A-allele) showed a trend towards a higher risk of grade ⩾3 peripheral neuropathy (*P*=0.075) ([@bib12]). In 118 patients with solid tumours receiving a variety of paclitaxel-containing combination schedules, Leskelä *et al* ([@bib19]) have described that *CYP2C8*\*3 (c.416G\>A) was significantly associated with the cumulative dose until grade 2 neurotoxicity. In that study, an incremental HR of 1.72 (*P*=0.032) per variant allele was calculated after adjustment for treatment schedule and age. In another study including 343 patients with mostly breast cancer and ovarian cancer, the *CYP2C8\*3* genotype (c.416G\>A and/or c.1196A\>G) was not indicative of maximum severity of peripheral neuropathy, whereas a trend was observed for total paclitaxel dose (mg) until grade \>2 peripheral neuropathy in the assessable subset of 146 patients ([@bib18]). Altogether, these and our findings indicate that *CYP2C8*\*3 is important in the occurrence of paclitaxel-induced neurotoxicity.

*CYP3A4* represents another major metabolising enzyme of paclitaxel. A novel genetic variant *CYP3A4* c.522-191C\>T has recently been identified as possible risk factor for paclitaxel-induced neurotoxicity. In the exploratory analysis of 135 males and 126 females treated with different paclitaxel-based schedules, female carriers of a T-allele were at increased risk of developing a higher grade of neuropathy (*P*=0.043) ([@bib8]). Validation in 129 males and 110 females also showed that more females than males developed neurotoxicity (*P*\<0.0001). For T-allele carriers an increased risk of development of grade 3 neuropathy was found in both genders, although only 2.5% of patients experienced severe symptoms. We could not confirm *CYP3A4* c.522-191C\>T as a possible risk factor for neurotoxicity grade ⩾1 in female carriers.

The biological relevance of *FGD4*, a protein involved in neuronal myelination, is best exemplified by Charcot--Marie--Tooth (CMT) disease, a congenital disease characterised by early onset of motor and sensory neuropathy ([@bib25]). A mutational change in *FGD4*, among other proteins, is believed to be closely related to the development of CMT. In this regard, genetic variants in *FGD4* may be of clinical significance in paclitaxel-induced neurotoxicity. Our analysis indicated that the presence of an A-allele in *FGD4* c.2044-236G\>A was associated with a decreased paclitaxel cumulative dose until first reduction due to toxicity and an increased risk of dose reduction (HR of 1.38 per A-allele). This finding has not yet been documented in paclitaxel-treated patients. In a recent GWAS of 855 Caucasian patients with primary breast cancer receiving adjuvant dose-dense paclitaxel 175 mg m^−2^ every 2 weeks × 4 or × 6, *FGD4* c.2044-236G\>A was associated with a lower cumulative dose until initial onset of grade ⩾2 sensory neuropathy (HR per A-allele=1.57, *P*=2.6 × 10^−6^, [@bib3]). Although the association did not reach statistical significance at a genome-wide level in the discovery phase, the predictive value of this A-allele was confirmed in two separate cohorts consisting of 154 European (HR per allele=1.72, *P*=0.013) and 117 African-American (HR per allele=1.93, *P=*6.7 × 10^−3^) patients. In our study on weekly paclitaxel 90 mg m^−2^, the presence of variants in *FGD4* c.2044-236G\>A was not predictive for grade ⩾1 peripheral neuropathy. The discrepancy with the results of [@bib3] might be explained by the different dosing regimens. It has to be mentioned, however, that the association of *FGD4* c.2044-236G\>A with first dose reduction includes severe cases of peripheral neuropathy among other paclitaxel-related AEs. As no other data exist, the clinical relevance of *FGD4* c.2044-236G\>A in paclitaxel-induced neurotoxicity deserves further investigation.

Leandro-García *et al* ([@bib17]) have been the first to identify three variants, that is, c.-101T\>C, c.-112A\>G, and c.-157A\>G (rs9501929) located in the *TUBB2A* promoter that correlated with increased mRNA levels. The c.-101T\>C and c.-112A\>G variants, in total linkage disequilibrium, conferred an increased transcription rate, whereas the transcriptional activity of the independent c.-157A\>G variant was not different from that of the wild-type promoter. The group hypothesised that their observation might provide a biological basis explaining differences in paclitaxel-induced AEs among patients. In the subsequent study in 214 paclitaxel-treated patients, they demonstrated that the presence of the c.-101C/c.-112G variant was protective against developing grade 2 neurotoxicity (HR=0.62, *P*=0.021) in a multivariate analysis in which a weekly or a 3-weekly schedule was taken into account. There was no association between the c.-157A\>G variant and paclitaxel-induced neurotoxicity ([@bib17]). In our study, *TUBB2A* c.-101T\>C was not associated with paclitaxel-induced peripheral neuropathy, but showed an association with paclitaxel dose reduction at a borderline significant level (HR per C-allele=0.70). In contrast to the findings of Leandro-García *et al* ([@bib17]), in a large cohort of 1303 patients with early breast cancer on paclitaxel-based therapy, *TUBB2A* c.-157A\>G was identified with respect to sensory neuropathy ([@bib1]). The minor allele appeared to be associated with an increased risk of grade ⩾2 sensory neuropathy (odds ratio 1.80, 95% CI 1.20--2.72), whereas the cumulative dose until this endpoint was also lower in carriers (HR 1.60, *P*=0.005).

Here, we attempted to validate *EPHA5* c.2895G\>A previously identified in two GWAS as a potentially useful toxicity marker, but no significant association was found in the current study. Ephrin Type-A receptor genes have been incorporated in other analyses. In a cohort of 144 patients with solid tumours treated with paclitaxel and carboplatin, several genetic variants were associated with cumulative dose-dependent grade 2 peripheral neuropathy, although the predefined significance level was not met ([@bib16]). Among them were *EPHA4* rs17348202 (HR=4.85, *P=*1.02 × 10^−6^) and several genetic variants located in Ephrin Type-A receptors *EPHA5*, *EPHA6* and *EPHA8*. Baldwin *et al* ([@bib3]) have performed GWAS in 855 breast cancer patients treated with paclitaxel to analyse two toxicity endpoints including the cumulative dose until first onset of grade ⩾2 sensory neuropathy and the maximum severity. For the first endpoint, *EPHA5* c.2898G\>A showed a borderline significant association (HR=1.63, *P*\<9.6 × 10^−7^), but this association could not be validated in two independent cohorts. A meta-analysis of data from both GWAS in a total number of 998 patients demonstrated *EPHA5* c.2898G\>A as a significant risk factor for developing sensory peripheral neuropathy (HR=1.68, *P*=1.4 × 10^−9^) ([@bib16]).

Several limitations in the present study warrant discussion. First, patient\'s ethnicity data were not collected, but most patients were presumed to be of Caucasian origin. This is also likely according to the variant allele frequency resembling that of the population of European descent, that is, CEU population of HapMap ([Table 1](#tbl1){ref-type="table"}). Second, we did not account for multiple comparisons given the exploratory or confirmatory nature of this study, because of which results should be interpreted within this context. Third, SNPs with low minor allele frequency may require a large sample size to achieve adequate power for statistical testing. Fourth, patients were treated with weekly paclitaxel 90 mg m^−2^ given as 3 weeks on/one week off (AT) or as 2 weeks on/one week off (ATX), whereas we combined both patients\' groups. The rates of peripheral neuropathy or dose reduction, however, were not different between the two paclitaxel schedules. The multivariate analysis was used to control for the potential confounding effect of differences in the total cumulative dose of paclitaxel, age and BSA. Finally, the call rate of SNP was deemed acceptable (\>90%) for genotyping using serum DNA and applying a pre-amplification step. A negative control and technical replicates were included to minimise genotyping error and to ensure accuracy of the results.

In conclusion, several genetic variants have previously been identified to be potentially useful for the prediction of paclitaxel-induced peripheral neuropathy. Results from earlier studies, however, are not always consistent, which may be due to variations in methodologies ([@bib9]). In our analysis, we could confirm that *CYP2C8\*3* was associated with an increased risk of peripheral neuropathy. There was an increased risk of early paclitaxel dose reduction for carriers of the *FGD4* c.2044-236 A-allele. These data are of value to add to the current knowledge of factors that might contribute to the differential toxicity from paclitaxel experienced among patients. In particular, our findings point towards *FGD4* c.2044-236G\>A as a SNP to be incorporated in future pharmacogenetic studies to further assess its role in taxane-related peripheral neuropathy.
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![**Kaplan--Meier curve of cumulative paclitaxel dose until the occurrence of grade ⩾1 peripheral neuropathy according to *CYP2C8*\*3 (*n*=180).**](bjc2016326f1){#fig1}

![**SNPs associated with paclitaxel dose reduction.** (**A**) Kaplan--Meier curve of cumulative paclitaxel dose until first dose reduction according to *FGD4* c.2044-236G\>A (*n*=186). (**B**) Kaplan--Meier curve of cumulative paclitaxel dose until first dose reduction according to *TUBB2A* c.-101T\>C (*n*=182).](bjc2016326f2){#fig2}

###### Allele frequency of investigated SNPs

  **Genetic variant**        **Reference SNP cluster ID**   **No. of patients**   **Homozygous wild-type,** ***n*** **(%)**   **Heterozygous variant,** ***n*** **(%)**   **Homozygous variant,** ***n*** **(%)**   **Frequency variant allele in this population**   **Frequency variant allele (Caucasian)**[a](#t1-fn2){ref-type="fn"}   **Frequency variant allele (Global)**[a](#t1-fn2){ref-type="fn"}   **Call rate, %**   **HWE *P* value**
  ------------------------- ------------------------------ --------------------- ------------------------------------------- ------------------------------------------- ----------------------------------------- ------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------ ------------------ -------------------
  *CYP2C8\*3* (c.416G\>A)             rs11572080                    180                  non-carriers/GG 146 (81.1)                   \*3 carriers/GA 34 (18.9)                            AA 0                                        0.094 (A)                                                     0.11                                                                0.065                                        96                0.16
  *CYP3A4* c.522-191C\>T              rs35599367                    172                         CC 154 (89.5)                                CT 17 (9.9)                                TT 1 (0.6)                                     0.055 (T)                                        0.05[b](#t1-fn3){ref-type="fn"}                                                  0.022                                        91                0.49
  *TUBB2A* c.-101T\>C                  rs909964                     182                         TT 100 (54.9)                               TC 68 (37.4)                                CC 14 (7.7)                                    0.26 (C)                                         0.26[b](#t1-fn3){ref-type="fn"}                                     0.43[b](#t1-fn3){ref-type="fn"}                           97                0.61
  *FGD4* c.2044-236G\>A               rs10771973                    186                         GG 86 (46.2)                                GA 79 (42.5)                               AA 21 (11.3)                                    0.33 (A)                                                      0.28                                                                 0.23                                        99                0.66
  *EPHA5* c.2895G\>A                  rs7349683                     172                         GG 77 (44.8)                                GA 69 (40.1)                               AA 26 (15.1)                                    0.35 (A)                                                      0.40                                                                 0.31                                        91                0.11

Abbreviations: HWE=Hardy--Weinberg equilibrium; SNP=Single-nucleotide polymorphism.

Frequency as reported in the SNP Database.

Frequency as reported in 1000 genomes.

###### Baseline patient and demographic characteristics (*n*=188)

  **Characteristic**                                                               **Study population,** ***n*** **(%)**
  ------------------------------------------------------------------------------- ---------------------------------------
  Age, years, median (range)                                                                    57 (32--76)
  Weight, kg, median (range)                                                                   71 (43--150)
  Body surface area, m^2^, median (range)                                                    1.79 (1.36--2.70)
  Baseline ECOG performance status[a](#t2-fn2){ref-type="fn"}                                         
   0                                                                                              99 (53)
   1                                                                                              89 (47)
  Oestrogen receptor and/or progesterone receptor                                                     
   Positive                                                                                      164 (87)
   Negative                                                                                       24 (13)
  Metastases at initial diagnosis                                                                     
   Yes                                                                                            25 (13)
   No                                                                                            163 (87)
  Sites of metastatic disease                                                                         
   Lung metastasis                                                                                63 (34)
   Liver metastasis                                                                              116 (62)
   Bone-only disease                                                                              10 (5)
  No. of metastatic sites                                                                             
   1                                                                                              23 (12)
   2                                                                                              69 (37)
   ⩾3                                                                                             96 (51)
  Prior (neo)adjuvant chemotherapy                                                                    
   Anthracycline-containing                                                                       94 (87)
   CMF                                                                                            12 (11)
   Other                                                                                           2 (2)
  Radiotherapy                                                                                        
   Primary breast cancer                                                                         122 (65)
   Recurrent or metastatic breast cancer                                                          64 (34)
  Preexisting diabetes mellitus                                                                       
   Yes                                                                                             3 (2)
   No                                                                                            185 (98)
  Pre-treatment biochemical values of liver and kidney function, median (range)                       
   Aspartate aminotransferase, U l^−1^ (*n*=188)                                               33 (13--250)
   Alanine aminotransferase, U l^−1^ (*n*=187)                                                  28 (6--340)
   Alkaline phosphatase, U l^−1^ (*n*=186)                                                     113 (40--690)
   Total bilirubin, *μ*mol l^−1^ (*n*=186)                                                       7 (2--27)
   Albumin, g l^−1^ (*n*=181)                                                                   42 (25--51)
   Blood urea nitrogen, mmol l^−1^ (*n*=158)                                                  4.9 (2.2--15.5)
   Serum creatinine, *μ*mol l^−1^ (*n*=188)                                                    67 (35--145)

Abbreviations: CMF=cyclophosphamide, methotrexate and fluorouracil; ECOG=Eastern Cooperative Oncology Group.

Patients with ECOG PS ⩾2 were excluded from clinical trial.

###### Paclitaxel cumulative dose, dose reduction and peripheral neuropathy

                                                                       **All patients (*****n*****=188)**   **AT arm (*****n*****=95)**   **ATX arm (*****n*****=93)**   ***P*** **value**[a](#t3-fn1){ref-type="fn"}
  ------------------------------------------------------------------- ------------------------------------ ----------------------------- ------------------------------ ----------------------------------------------
  Median cumulative dose, mg m^−2^ (range)                                      1409 (90--1709)                  1519 (120--1709)               1351 (90--1534)                            \<0.001
  Median relative dose intensity[b](#t3-fn2){ref-type="fn"} (range)            0.94 (0.06--1.18)                 0.94 (0.07--1.18)             0.94 (0.06--1.18)                             0.28
  **Peripheral neuropathy,** ***n*** **(%)**                                                                                                                            
  Grade 1                                                                          68 (36.2)                         34 (35.8)                     34 (36.6)                                   
  Grade 2                                                                          41 (21.8)                         18 (18.9)                     23 (24.7)                                   
  Grade 3                                                                           17 (9.0)                          9 (9.5)                       8 (8.6)                                    
  No peripheral neuropathy                                                         62 (33.0)                         34 (35.8)                     28 (30.1)                                   
  Dose reduction, *n* (%)                                                           87 (46)                           42 (44)                       45 (48)                                  0.57

*P* value from comparison between AT and ATX arm.

Relative dose intensity was calculated as the ratio between actual paclitaxel dose given in a time period (mg m^−2 ^week^−1^) and planned dose during 24 weeks of paclitaxel-containing therapy considering no dose modification. Cases of progression or death within 24 weeks were included until the events. Patients taken off study due to toxicity were included until the end of planned paclitaxel-containing therapy.

###### Analyses of SNPs and possible association with peripheral neuropathy or paclitaxel dose reduction

                                                              **Peripheral neuropathy**   **Paclitaxel dose reduction**                                     
  ------------------------- -------------------------------- --------------------------- ------------------------------- ------- ------ ------------------- -------
  *CYP2C8\*3* (c.416G\>A)   \*3 carriers *vs* non-carriers              0.018                   1.59 (1.01--2.52)         0.045   0.81                          
  *CYP3A4* c.522-191C\>T    Dominant (TT+CT *vs* CC)                    0.44                                                      0.14                          
  *TUBB2A* c.-101T\>C       Additive                                    0.83                                                      0.16   0.76 (0.53--1.10)   0.14
                            Dominant (CC+TC *vs* TT)                    0.66                                                      0.10                          
                            Recessive (CC *vs* TC+TT)                   0.59                                                      0.13                          
  *FGD4* c.2044-236G\>A     Additive                                    0.62                                                      0.10   1.38 (1.02--1.86)   0.036
                            Dominant (AA+AG *vs* GG)                    0.46                                                      0.04                          
                            Recessive (AA *vs* AG+GG)                   0.39                                                      0.18                          
  *EPHA5* c.2895G\>A        Additive                                    0.77                                                      0.28                          
                            Dominant (AA+AG *vs* GG)                    0.84                                                      0.13                          
                            Recessive (AA *vs* AG+GG)                   0.48                                                      0.27                          

*P* value was calculated from the Gehan--Breslow--Wilcoxon test. SNPs with *P*\<0.10 were selected for the Cox proportional hazards analysis.

Multiplicative genetic model, hazard ratio per variant allele except for *CYP2C8\*3.*

Hazard ratio adjusted for age, body surface area, cumulative paclitaxel dose in tertiles.

Hazard ratio adjusted for cumulative paclitaxel dose in tertiles.
